Some people may refer to the condition as diabeticmacular retinal oedemaoroedema of the eyes. Diabetic macular edema is among the top causes of vision loss, both globally and within the United States. Worldwide, approximately 100 million individuals have signs of the condition. More than 75,000...
The article presents detailed information on macular oedema. It is defined as the accumulation of fluid in retinal layers around the fovea. Its causes include diabetes, retinal vascular disease, age-related macular degeneration (AMD), uveitis, and vitreoretinal traction. It is stated that typically...
Farber MD, Lam S, Tessler HH, Jennings TJ, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol. 1994;78:4–7. Schilling H, Heiligenhaus A, Laube T, et al. Long-term effect of...
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists Article Open access 30 August 2024 LRG1 as a novel therapeutic target in eye disease Article Open access 05 Januar...
KSI-301 (Kodiak Sciences Inc., Palo Alto, California) is a novel intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate (ABC) being evaluated for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein oc...
Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse after successful treatm
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries. Ophthalmol Therapy. 2023;12:809–26. Article Google Scholar Bourne R, Steinmetz JD, Flaxman S, Briant PS, Taylor HR, Resnikoff S, Casson ...
A non-interventional, longitudinal, retrospective follow-up study to assess CsA-induced nephrotoxicity (IN) and its reversibility after withdrawal in patients exhibiting a bilateral chronic posterior uveitis (CPU) associated with cystoid macular oedema (CMO) in at least one eye. Data from medical rec...
Diabetic macular oedema (DMO) is responsible for significant visual impairment in diabetic patients. The primary cause of DMO is fluid leakage resulting from increased vascular permeability through contributory anatomical and biochemical changes. These i
Estimates of the DMO prevalence rate range from around 1 to 12% of all people with diabetes.57 A study estimated 7% of people with diabetes in United Kingdom had DMO, and of these, more than one-third (39%) had clinically significant macular oedema with visual impairment (visual acuity ...